Suppurative lung disease Flashcards

1
Q

Classes of CFTR mutation

A

Class I: defective protein synthesis e.g. G542X
Class II: defective protein maturation and trafficking e.g. F508del
Class III: Impaired chloride channel opening (gating) e.g. G551D
Class IV: Defective channel ion transport (Conductance) e.g. R117H
Class V: Defective splicing
Class VI: Accelerated turnover at cell surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment of pseudomonas in CF

A

Colomycin nebs and PO ciprofloxacin 3 months
IV abx e.g. ceftazidine, tazocin, aztreonam, meropenem and tobramycin, amikacin, colomycin 2 weeks prior to PO switch

Maintenance:
colomycin or tobramycin nebs/DPI
aztreonam nebs
levofloxacin nebs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Treatment of staph aureus in CF

A

IV fluclox 2 weeks
add anti-staph antibiotic e.g. sodium fusidate or rifampicin for 2 weeks

If MRSA
4 week PO rifampicin with sodium fusidate
linezolid or neb vancomycin
IV teiciplanin or vancomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Treatment of haemophillus in CF

A

co-amox or doxy 2 weeks - even if asymptomatic
prolonged course - IV co-amox, ceftriaxone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment of burkholderia cepacia complex in CF

A

Sensitivities
Meropenem
ceftazidime
pip-taz
aminoglycosides
temocillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Treatment of stenotrophomonas maltophilia in CF

A

co-trimox
doxycycline
ticarcillin-clavulanic acid
tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Treatment of achromabacter xylosoxidans in CF

A

minocycline
meropenem
pip-taz
chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

tCFTR modulators

A

Ivacaftor (Kalydeco) - CFTR potentiator, in G551D or other gating mutation
Tezaceftor-Ivacaftor (Symkevi/Symdeko) - homozygous for F508del or heterozygous for F508del (1st line)
Lumacaftor-Ivacaftor (Orkambi) - F508del homozygous
Triple therapy (Kaftrio) - one F508del mutation and one minimal function mutation and F508del homozygous patients - approved in NHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bronchiectasis severity index

A

age
BMI
FEV1
Hospital admissions in 2 years
exacerbations ibn 12 months
MRC
Pseudomonas colonisation
radiological severity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bronchiectasis infection treatment - first isolate of pseudomonas aeruginosa

A

2 weeks PO ciprofloxacin
IV pseudomonal penicillin (at least 2 weeks) with nebulised colistin, gentamicin, tobramycin for 3 months
Add IV amnioglycoside if lack of response

Colonised patient
long term nebs colistin or gentamycin
+/- macrolide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly